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Virgin olive oil contains phenolic compounds that were potential for anti-inflammatory and cancer 
treatment. Computational biology is a beneficial method to understand how this compound can affect the 
biological process in humans. This research is conducted by the potential screening of VOO compounds, 
constructing the pharmacological network and enrichment, and docking simulation. The enrichment result 
showed that the EGFR, BRAF, MAPK1, CCND1, and MDM2 protein have multiple cancer contributions and 
related pathways. The docking simulation result showed that the interaction of EGFR-luteolin, BRAF-
luteolin, MAPK1-luteolin, CCND1-apigenin, and MDM2-1-hydroxypinoresinol has the highest binding 
affinity. Further research with the in-vitro methods are required to check the reliable mechanisms of each 
compound to their protein target. 
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INTRODUCTION  
The virgin olive oil (VOO) is the main 
product of olive trees (Olea europaea subs. 
Eureupaea). This tree is a symbolic species in the 
Mediterranean region. Genomic research with this 
tree is important for facilitating study in 
metabolisms, developmental and physiological 
process, which is the research could contribute to 
improving the economic values of this tree (Cruz et 
al., 2016). Extra VOO contains dominant phenolic 
compounds (Visioli and Bernardini, 2011), which 
those compounds have different classes, such as 
phenyl ethyl alcohols, steroids, phenolic acids, 
hydroxy-isochromans, lignans and, flavonoids. The 
phenolics (also known as polyphenols) from a 
plant have some benefits in the human body to 
prevent various diseases. They work to bind 
several proteins, which may lead to a specific 
disease, and they have also antioxidants activity 
against free-radical (Preedy and Watson, 2010). In 
the in-vitro studies, they can modulate 
intracellular signaling pathways; so, VOO 
compounds, like hydroxytyrosol, tyrosol, and other 
minor compounds, have been the focus of research 
to see its effect in the biological process (Serreli 
and Deiana, 2018).  
Recent studies in-vitro and in-vivo with VOO 
compounds have been done. The recent studies, 
hydroxytyrosol from VOO has been reported could 
induce cell cycle arrest  and  apoptosis  on  various 
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cells, such as colon cancer cells, bladder cancer and  
cholangiocarcinoma  (Coccia et al., 2016; Li et al., 
2014; López de las Hazas et al., 2017). Pinoresinol 
may also probably have antitumor activity in 
breast cancer cells (López-Biedma et al., 2016), and 
p-HPE-EDA can inhibit colon cancer cells with 
inhibition of AMP-activation protein kinase 
(AMPK) and cyclooxygenase-2 (COX-2) (Khanal      
et al., 2011). In silico and in vitro study showed that 
oleuropein confirmed could inhibit mTOR, which is 
responsible for tumor cells’ properties on breast 
cancer (Corominas-Faja et al., 2018).  
World health organization (WHO) 
mentioned that cancer which causes the death of 
about 9.6 million death in 2018, is a group of 
diseases with abnormal cell growth that can invade 
other organs. The mechanisms in this disease are 
very complicated. Researchers mention that this 
disease is mainly caused by a gene mutation 
affecting cell functions, carcinogenic chemical 
compounds, and an unhealthy lifestyle 
(Hassanpour and Dehghani, 2017). Genetic 
materials and proteins play an essential role in this 
group’s diseases; with bioinformatics, it will more 
easily explore potential clinical applications and 
improve diagnosis, therapies, and cancer diseases 
prognosis (Wu et al., 2012). Computational 
network biology is a new research field that 
involves theory and applications to describe a 
molecule’s interaction on living cells; this field also 
contributes to accelerating molecular biology, 
pharmacology, and genetics studies (Ni et al., 
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and analyzing big data;  with  this  network  model, 
the extensive information of the biological system 
could be more easily to be understanding  (Ideker 
and Nussinov, 2017; Ma’ayan, 2011).  
 
METHODOLOGY 
Preparation of ligand and protein target  
VOO bioactive compounds were collected 
from the PubChem database (https://pubchem. 
ncbi.nlm.nih.gov/) based on relevant literature 
(Alavi and Golmakani, 2017; Basiricò et al., 2019; 
Rupani, 2014; Waterman, 2007; Zalejska-Fiolka      
et al., 2015). Finally, 16 bioactive compounds used 
in this study were listed in Table I. The 3D 
structure and canonical SMILES of all compounds 
were downloaded from the PubChem database. 
Canonical SMILES compounds were used for 
identifying the potential target proteins on the 
Phrammapper web server (http://lilab-ecust.cn/ 
pharmmapper/) and Swiss Target Prediction web 
server (http://www. swisstargetprediction.ch/). 
Phrammapper web server is a platform for 
identifying the potential protein target from 
bioactive compounds with statistical method 
calculation include more than 7000 target 
pharmacophores (X. Liu et al., 2010; X. Wang et al., 
2017). The specification for searching target 
proteins was set as Druggable Pharmacophore 
Models (v2017,16159) (Liang et al., 2019). Like a 
Phrammapper webserver, SwissTargetPrediction 
is an accruable webserver to predict the target 
proteins of bioactive compounds (Gfeller et al., 
2014); this web server has been updated for 
efficient prediction of protein targets (Daina et al., 
2019). The result from Phammapper and 
SwissTargetPrediction webserver was saved as 
.csv format and used to construct network 
compound-protein interactions. 
 
Network construction and analysis 
The network compound-protein interaction 
was constructed by Cytoscape software and its 
plugins (https://cytoscape.org/). Excel files from 
Pharmmapper and SwissTargetPrediction that 
contains compound-protein interaction data were 
imported to Cytoscape software with the menu 
“import network form file system”. The compound 
table was selected as a “source node”, and the 
protein target was selected as a “target node”.      
The following analysis was used ClueGO 
Cytoscape’s plugins to show the interpretation of 
list genes on the metabolical process (Bindea et al., 
2009).        The ClueGO plugin’s setting performs as 
pathways with p-values ≤ 0.001, and the kappa 
score was set as 0.4. The Gene Ontology      
databases were used from the Kyoto Encyclopedia 
of Genes and Genomes (KEGG) and     
Wikipathways. The selected target proteins from 
the ClueGO enrichment were used for docking 
simulation for determining ligand-protein 
interaction.    
 
Protein Preparation and Molecular docking 
simulation 
The ClueGO results relating to cancer 
diseases were selected as a target protein for 
molecular docking. The target protein used for 
molecular docking were retrieved from Protein 
Data Bank (https://www.rcsb.org/). The 3D 
structure of proteins used in this study was listed 
as follows: EGFR-PDB.id 6LUD (Kashima et al., 
2020), BRAF-PDB.id 6NSQ (Assadieskandar  et  al.,  
Table I. Bioactive compounds in virgin olive oil 
 
No PubChem ID Compound Name 
1 5280934 alpha-Linolenic acid 
2 5280450 Linoleic acid 
3 445639 Oleic acid 
4 985 Palmitic acid 
5 5281 Stearic acid 
6 10393 Tyrosol (p-HPEA) 
7 82755 Hydroxytyrosol (3,4-DHPEA) 
8 131750845 1-(3-Methoxy-4-hydroxy)-phenyl-6,7-dihydroxy-isochroman 
9 442831 1-Acetoxypinoresinol 
10 13824420 1-Hydroxypinoresinol 
11 131750844 1-Phenyl-6,7-dihydroxy-isochroman 
12 124202093 3,4-DHPEA-EA 
13 5280443 Apigenin 
14 5280445 Luteolin 
15 16681728 p-Hpea-eda 
16 234817 Pinoresinol 
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2019), MDM2-PDB.id 3LNJ (M. Liu et al., 2010), 
MAPK/ERK-PDB.id 5NHH (Ward et al., 2017), and 
CCND1 6P6G (Guiley et al., 2019). Those target 
proteins were sterilized from waters and ligands 
using PyMOL software (available in 
https://pymol.org/2/). The ligands used for 
molecular docking simulation were converted to 
.pdbqt format using open babel on PyRx software 
(available in https://pyrx.sourceforge.io/), and the 
reverse docking simulation was performed using  
Vina Wizard in PyRx (Dallakyan and Olson, 2015; 
Trott and Olson, 2010). The docking results were 
visualized and evaluated using PyMOL software. 
The interaction between amino acid residues and 
ligands in 2D view were visualized using BIOVIA 
DiscoveryStudio 2019 software (available in 
https://www.3dsbiovia.com/). 
 
RESULT AND DISCUSSION  
Preparation of ligand and network data 
construction 
Sixteen potential ligands from VOO were 
collected from PubChem, and the list of             
protein targets from Phrammapper and 
SwissTargetPrediction were downloaded.            
Each compound interacted with various proteins 
that may contribute to many functions on 
biological pathways to build the compound-
proteins network. Network construction with 
Cytoscape software showed 1639 nodes and 4016 
edges. A node represents the target proteins and 
VOO compounds, while an edge represents the 
interaction of compounds–target proteins on the 
biological pathways (Figure 1). The VOO 
compounds labeled with red nodes in Figure 1 
interact with blue nodes labeled as target proteins. 
Luteolin, 1-Hydroxypinorisenol, apigenin, linoleic 
acid, pinoresinol, oleic acid, stearic acid, 1-
Acetoxypinorisenol, palmitic acid, p-Hpea-eda, and 
alpha-linolenic acid are located on central of nodes 
target protein, and other compound’s nodes are 
located on outside of central interaction.               
Table panel protein target interactions from the 
Cytoscape network were saved as an Excel file.       
All protein was filtering and grouping to determine 
their biological pathways using ClueGO 
Cytoscape’s plugin. 
 
Network construction and analysis 
ClueGO analysis with KEGG and gene 
ontologies database showed 26 nodes and 38 
edges with three pathways (Figure 2a),                       
and WikiPathways database 35 nodes and 59 
edges with four pathways (Figure 2b). ClueGO’s 
plugin pathways were listed in Table 2; this result 
showed that VOO compounds are associated with 
various pathways, especially in tumor and cancer.             
The VOO compounds interact with various 
proteins that work on several biological pathways 
and are interconnected with its pathway or other 
pathways. From the KEGG database and 
WikiPathways database enrichment, it has known 
that VOO compounds’ target protein was probably 
related to cancer disease  and  tumor with a                
p-value ≤ of 0.001. A significant test of the p-value 
is vital for decision-making. A very small p-value 
indicated that the hypothesis is probably correct 
(Panagiotakos, 2008). These enrichment pathways 
indicated that they have a high confidence value. 
All pathways from ClueGO are related to 
each other indicated that the several nodes of the 
gene connect with all pathways in Figure 2 
(marked with a red circle). Glioma is the one type 
of   tumours  disease   that   occurs   in   the  Central 
 
 
Figure 1. The network interaction from Cytoscape of 16 compounds of VOO with their target proteins 
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Nervous System (CNS) and spinal cord; this disease 
is a common type of primary malignant brain 
tumor derived from glial cells (Ernest and 
Sontheimer, 2009). Glioblastoma or glioblastoma 
multiforme (GBM) is a subclass of glioma disease 
(JOVČEVSKA et al., 2013).  
Oncostatin M (OSM) is an important 
pathway associated with the biological process and 
cellular responses. This pathway is vital for clinical 
and biomedical therapeutic on the human disease 
(Dey et al., 2013). OSM pathway has been reported 
associating with cancer cell’s plasticity (Junk et al., 
2017); also contribute to breast tumor specifically 
mediated by OSMRβ (Underhill-Day and Heath, 
2006) and prostate cancer (Godoy-Tundidor et al., 
2005). Prostate cancer and bladder cancer are 
double cancer primary cancer with high frequency 
reported; this data suggest that the patients 
diagnosed with bladder or prostate cancer should 






Figure 2. ClueGO grouping shows the biological pathway from the list of the genes from the network.                 
(a) KEGG database; (b) Wikipathways database. 
 
Table II. ClueGO enrichment pathways with KEGG pathways database and WikiPathways database 
 
No Source Database Pathway Colour P-Value 
1 KEGG ontologies Prostate cancer Avocado green 7.77 x 10-9 
2 KEGG ontologies Bladder cancer Turquoise 4.13 x 10-6 
3 KEGG ontologies Glioma Dull green 3.60 x 10-6 
4 Wikipathways Glioblastoma Blue 7.66 x 10-8 
5 Wikipathways Bladder cancer Turquoise 6.28 x 10-6 
6 Wikipathways Oncostatin M signalling pathway Green 1.49 x 10-6 
8 Wikipathways  Matrix metalloproteinases Dull green 4.37 x 10-6 
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(Kinoshita      et al., 2004). Disturbing the OSM 
pathway may is potential for cancer cell treatment 
(Caffarel and Coleman, 2014; Stroeder  et al., 
2018).  
The other pathway, Matrix 
metalloproteinases (MMPs), is a group of enzymes 
responsible for the degradation of extracellular 
matrix protein during organogenesis and normal 
tissue replacement. This group of enzymes is also 
associated with oral cancer (Sorsa et al., 2004). 
Based on ClueGO enrichment, it is shown that this 
pathway has a connection with bladder cancer and 
OSM. The interruption of this protein activity could 
lead to various diseases (Laronha and Caldeira, 
2020). 
From KEGG and Wikipathways database 
enrichment, five genes contribute to OCM, glioma, 
bladder, and prostate cancer pathways. Those 
genes are CCND1 encodes G1/S-specific cyclin-D1 
protein, MAPK1 encodes dual specificity mitogen-
activated protein kinase 1, MDM2 encodes E3 
ubiquitin-protein ligase Mdm2, EGFR encodes 
epidermal growth factor receptor protein, BRAF 
encodes serine/threonine-protein kinase B-RAF. 
These proteins were chosen for molecular docking 
simulation docked with the compound from VOO 
as the ligand to know their interaction. They could 
be evaluated to be used as therapeutic compounds 
for treating cancer disease.  
The CCND1 (Cyclin D1) gene has a function 
in the regulation of CDK kinase in the cell cycle; 
when this gene had the mutation and 
overexpressed, it can promote a various type of 
cancers disease in humans, such as breast cancer, 
endometrial cancer, colon cancer, and prostate 
cancer (Fu et al., 2004; Ikeda et al., 2013; Moreno-
Bueno et al., 2003; Xu and Lin, 2018). This gene is 
also used as a biomarker in breast cancer 
(Lundberg et al., 2019). Cyclin D1 protein functions 
as cyclin-dependent-kinase (CDK) in a subunit of 
CDK4 or CDK6 to regulate the cell cycle from G1 to 
S phase transition. They act as apoptosis regulators 
interacting with tumor suppressor protein 
retinoblastoma (Rb) to interrupting the cell cycle. 
CCND1 also acts on chromatin recruitment, 
mitochondrial biogenesis, and DNA Damage 
Response (DDR) (Fu et al., 2004; Massagué, 2004; 
Pestell, 2013). When this gene act as an oncogene 
caused by point mutation, local DNA 
rearrangements, or chromosomal translocation, 
then they could overexpress in a cell, and that cell 
will have rich of complex CDK-cyclin; so, it could 
stimulate the progression in cell cycles, stimulate 
tumorigenesis, and metastases even in the absence 
of growth factor (Fu et al., 2004; Hardin et al., 2012; 
Kim and Diehl, 2009).  
 
The murine double minute 2 (Mdm2) gene 
encodes a protein acting as a negative regulator of 
the p53 tumor suppressor. These genes’ 
overexpression occurs in many tumors (Iwakuma 
and Lozano, 2003; Senturk and Manfredi, 2012). 
Mdm2 most commonly associated with 
liposarcoma compared with breast cancer and 
bladder cancer in MD Anderson phase 1 clinic 
(Dembla et al., 2018), and Mdm2 amplification not 
in most tumor types, that is just in the small subset 
in types tumor (Kato et al., 2018). The Mdm2 
interacts with p53 protein to make p53 inactive, 
and this mdm2-p53 interaction can cause 
apoptosis failure (Hardin et al., 2012). Activation of 
p53 protein is critical to protect the propagation 
cells from damaged DNA with oncogenic mutations 
and control the cell cycle (Moll and Petrenko, 
2003). Blocking the Mdm2-p53 and Mdm-non p53 
interaction is a promising cancer therapeutic 
strategy (Shangary and Wang, 2008; S. Wang et al., 
2017).  
BRAF encodes Raf protein and MAPK1/2 
gene-encoded mitogen-activated protein kinase 
1/2 or Extracellular Signal-Regulated Kinases 
(ERKs) protein which play on signal transduction 
in the MAPK signaling pathway. This protein is 
known as signal transduction which works on the 
Ras-Raf-MEK-ERK signaling for cell proliferation, 
cell differentiation, cell metastasis, cell survival, 
and apoptosis (Mansfield et al., 2018; Mebratu and 
Tesfaigzi, 2009; Thatcher, 2010). Activating this 
pathway starts with growth factor family protein 
like Epidermal Growth Factor (EGF) binds their 
receptor to phosphorylate Raf protein as 
downstream of Ras on the MAPK signaling 
pathway (Ursem et al., 2018). Altered of this 
signaling pathway or mutation in genes encoding 
the protein in this pathways have been reported 
correlated and detected in tumors and cancer 
disease, including in pituitary tumourigenesis, 
cervical cancer tissue, and significantly correlated 
on breast cancer with axillary lymph node 
metastasis (Suojun et al., 2012; Manousaridis et al., 
2013 Jan 1; Li et al., 2015: 1; AACR  Project GENIE 
2017; Shao et al., 2018). The inhibitors with 
targetting on these kinases protein could treat 
malignant tumors; this inhibitor would be 
promising and challenging in future research (Liu 
et al., 2018; Suojun et al., 2012). National 
Comprehensive Cancer Network (NCCN) also 
recommending BRAF testing gene for diagnosis of 
colorectal cancer (CRC) (Ursem et al., 2018).   
 
Molecular Docking Simulation 
Computational methods recently used in the 
biotechnology and pharmaceutical industries were  
Achmad Rodiansyah 
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beneficial for drug discovery with high success and 
accuracy and reduced costs (Parenti and Rastelli, 
2012; Suortti, 1997).  Reverse docking is a 
promising drug prediction technique that acts on 
protein-related disease as inhibitors (Kharkar          
et al., 2014); this method has excellent drug design 
and drug discovery success. The docking 
simulation result showed that VOO compounds 
have various docking scores to target proteins 
(Figure 3). 
The bar chart in Figure 3 shows the docking 
simulation score from VOO compounds with their 
target proteins. The deep-blue chart is an EGFR 
protein; an orange chart is a BRAF protein; a yellow 
chart is a MAPK protein; a grey chart is an MDM2 
protein, and a blue chart is a CCND1 protein. 
Luteolin from VOO has the highest docking score,     
-7.9 kcal/mol on EGFR protein and -9.5 kcal/mol 
on BRAF protein. 1-Hydroxypinoresinol has the 
highest docking score with -7.0 kcal/mol on MDM2 
protein. Apigenin has the highest docking score 
with -6.7 kcal/mol on CCND1 protein; also,                 
on MAPK protein, luteolin has the highest docking 
score of -9.0 kcal/mol, respectively (Figure 3). 
Compared to the control compound, only the 
docking score from Luteolin-BRAF and luteolin-
MAPK were more stable. The docking score from 
control compounds was listed in Table III. 
 
Figure 3. Docking result of the compounds with selected protein from KEGG and WikiPathways database 
 
Table III. Docking score from control compounds 
 
No Ligand PubChem Id Protein Score (kcal/mol) Label 
1 Osimertinib 71496458 EGFR -8.3 Red 
2 Vandetanib  3081361 EGFR -8.1 Magenta 
3 Encorafenib 50296675 BRAF -8.7 Red 
4 Vemurafenib 42611257 BRAF -9.2 Magenta 
5 AMG-232 58573469 MDM2 -6.2 Red 
6 Idasanutlin 53358942 MDM2 -7.6 Magenta 
7 Vemurafenib 42611257 MAPK -8.6 Red 
8 Encorafenib 50296675 MAPK -7.4 Magenta 
9 CDK4 inhibitor 5330797 CCND1 -8.6 Red 
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Binding affinity is a critical aspect of drug 
design to produce potential ligands with high 
binding affinity to the target protein and low target 
binding affinity to non-targeted protein (Kairys       
et al., 2019). The Gibbs energy of binding (ΔGb) or 
binding affinity is value to define a strong 
interaction between two molecules, so this is a 
crucial quantity for study molecule interaction 
(Vangone et al., 2018). The type of bond on reverse 
docking is critical on binding affinity as a docking 
score, especially the hydrogen bond in ligand-
protein interaction. The 2D visual interaction of the 
VOO ligands colored with green within their target 
protein can be seen in Figure 4, and the list of 
amino acid residues can be seen in Table IV. 
The results from molecular docking showed 
that the most of the ligands occupied the vital 
region of the protein. This interaction could 
potentially disrupt the work of target protein, like 
preventing phosphorylation and inhibiting protein 
activation. A ligands’ effectiveness to interfere with 
proteins’ action can be predicted by the docking 
score from the inhibitor ligand to the protein. Many 
factors that contribute to binding affinity score as 
follow: the role of water, the existence of H-bonds, 
the different types of the bind of ligand-protein 
interaction include ionic interactions, Van der 
Waals and hydrogen bond interaction, 
hydrophobic interaction, Pi-alkyl bond, and               
Pi-sulfur bond; those factors must be considered to 
evaluate docking results (Arthur and Uzairu, 2019; 
Pantsar and Poso, 2018). However, not all 
parameters can be calculated on this docking 
simulation, so an in-vitro and in-vivo study must be 
carried to determine the reliable responses 
(Pintilie and Stefaniu, 2019). 
The illustration of VOO compounds to 
inhibit the target protein can be seen in Figure 5. 
From this illustration, the VOO compounds 
probably can work on several fields on the cells, 
like on the extracellular-membrane layer, 
cytoplasm, and nucleus cells field. EGFR protein is 
located on membrane cell, MAPK1 and BRAF 
protein work on the cytoplasm, MDM2 and CCND1 
protein work on the nucleus. 
 
CONCLUSION 
The VOO compounds have multiple protein 
targets on various pathways, especially in cancers 
and tumors.  Five   proteins   that   act   on   multiple 
 
 
Figure 4. Molecular interaction VOO ligands with the target proteins. (a) EGFR; (b) BRAF; (c) MDM2;           
(d) MAPK; (e) CCND1. 
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Figure 5. The illustration of VOO compounds work on their target proteins in the cell (The illustration was 
created with BioRender. (Available at: https://biorender.com/) 
 
Table IV. Amino acid residues from molecular docking simulation with the highest score and the 
information domain from UniProt 
 
No Protein VOO ligand Amino acid residues Domain UniProt 
1 EGFR luteolin LEU718, GLY719, VAL726, ALA743, 
LYS 745 GLU762, LEU792, MET793, 
PRO794, GLY796, MET798, LEU844, 
THR854, ASP855 




2 BRAF luteolin ILE463, VAL471, ALA481, VAL482, 
LYS483, GLU501, VAL504, LEU505, 
THR508, ILE513, LEU514, ILE527, 
THR529, GLN530, TRP531, CYS532, 
LEU567, PHE583, GLY593, ASP594, 
PHE595  




3 MDM2 1-Hydroxypinoresinol LEU54, LEU57, GLY58, ILE61, MET62, 
TYR67, GLN72, HIS73, VAL93, VAL75, 
HIS96, ILE99, TYR100  
Uniprot Id: Q00987 
Region: 1-110 (USP 
interaction domain) 
4 MAPK1 Luteolin ILE31, GLY32, GLU33, GLY34, VAL39, 
ALA52, LYS54, ILE84, GLN105, 
ASP106, LEU107, MET108, GLU109, 
THR110, LYS114, LEU156, CYS166, 
ASP167 







5 CCND1 Apigenin ASN174, ILE178, ILE177, HIS181, 
VAL212, GLY214, LEU217, ARG218, 
PRO220, ASN222  
Uniprot Id: P24385 
Region: 2-208 
(Interaction region) 
Region: 2-19 (Region 
for RPLP0 & TCF3) 
Region: 150-360 
(Region for TCF3) 
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central pathways from KEGG and WikiPathways 
database were MAPK1, BRAF, EGFR, MDM2, and 
CCND1. The docking simulation showed that the 
luteolin compound was stable with EGFR protein 
and BRAF protein, with the docking score reaching 
about -7.9 kcal/mol and -9.5 kcal/mol, 
respectively; 1-hydroxypinoresinol was stable to 
interact with MDM2 protein, reaching a score of        
-7.0 kcal/mol; apigenin and stearic acid were 
stable to interact with CCND1 protein with docking 
score reaching -6.7 kcal/mol. Also, MAPK protein is 
stably interacting with luteolin, which has a 
docking score of -9.0 kcal/mol. Those compounds, 
especially luteolin, probably have the potential for 
therapeutic on various cancers and tumors. These 
docking simulation results also report that luteolin 
has a stronger binding affinity than the control 
compound for interfering with the BRAF and MAPK 
protein. The in-vitro and in-vivo study must be 
carried out to validate the specific response from 
ligands on proteins involved in cancer pathways. 
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